c108274.htm - Generated by SEC Publisher for SEC Filing

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549
 

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

April 22, 2013

________________

 

        NOVO NORDISK A/S        
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

logo.gif

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 22 April 2013 – On 31 January 2013 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 31 January 2013 to 29 April 2013.

Since the announcement as of 15 April 2013, the following transactions have been made under the programme:

 

 

Number of

Average

Transaction

 

shares

purchase price

value, DKK

Accumulated, last announcement

2,496,810

 

2,454,828,814

15 April 2013

45,000

959.95

43,197,732

16 April 2013

70,000

966.02

67,621,400

17 April 2013

70,000

953.74

66,761,856

18 April 2013

70,000

952.26

66,657,962

19 April 2013

60,000

951.32

57,079,314

Accumulated under the programme

2,811,810

 

2,756,147,078

 

With the transactions stated above, Novo Nordisk owns a total of 10,395,508 treasury shares, corresponding to 1.9% of the share capital. The total amount of shares in the company is 550,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14.0 billion during a 12 month period beginning 31 January 2013. As of 19 April 2013, Novo Nordisk has repurchased a total of 2,811,810 B shares equal to a transaction value of DKK 2,756,147,078.

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

CVR no:

Investor Relations

2880 Bagsværd

+45 4444 8888

24 25 67 90

Denmark

Internet:

 

 

www.novonordisk.com

 

 

 

 

Company announcement No 29 / 2013

         

 

 


 

 

 

 

Page 2 of 2

 

 

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.  

 

Further information

 

 

Media:

 

 

Anne Margrethe Hauge

+45 4442 3450

amhg@novonordisk.com

Ken Inchausti (US)

+1 609 514 8316

kiau@novonordisk.com

 

 

 

Investors:

 

 

Kasper Roseeuw Poulsen

+45 4442 4303

krop@novonordisk.com

Frank Daniel Mersebach

+45 4442 0604

fdni@novonordisk.com

Lars Borup Jacobsen

+45 3075 3479

lbpj@novonordisk.com

Jannick Lindegaard (US)

+1 609 786 4575

jlis@novonordisk.com

 

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

CVR no:

Investor Relations

2880 Bagsværd

+45 4444 8888

24 25 67 90

Denmark

Internet:

 

 

www.novonordisk.com

 

 

 

 

Company announcement No 29 / 2013

         

 

 

 

 

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 22, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer